Novo Nordisk establishes type 1 diabetes R&D center in Seattle
Taxonomy upgrade extras:
Novo Nordisk news
43 research talents awarded scholarships to help secure Denmark’s future
Taxonomy upgrade extras:
Novo Nordisk files for regulatory approval of the co-formulation insulin degludec/insulin aspart in Japan
Taxonomy upgrade extras:
Statement from Novo Nordisk regarding the petition to the FDA by Public Citizen
Taxonomy upgrade extras:
Two phase 3 studies on ultra-long-acting insulin degludec published today in The Lancet
Taxonomy upgrade extras:
Novo Nordisk and Oxford University team up to develop novel treatments for rheumatoid arthritis and other inflammatory diseases
Taxonomy upgrade extras:
Novo Nordisk receives positive opinion on recombinant factor XIII from the European regulatory authorities
Taxonomy upgrade extras:
Investigational ultra-long-acting insulin degludec reduces rates of nocturnal hypoglycaemia in type 2 diabetes patients versus insulin glargine
Taxonomy upgrade extras:
A new study with 'real world' data shows greater efficacy of Victoza(R), with weight loss and cost-effectiveness, in type 2 diabetes compared to twice-daily exenatide and DPP-4 inhibitors
Taxonomy upgrade extras:
Global survey finds one in four type 2 diabetes patients do not take basal insulin as prescribed and more than a third suffer from hypoglycaemia
Taxonomy upgrade extras:
JDRF and Novo Nordisk establish R&D collaboration in type 1 diabetes
Taxonomy upgrade extras:
Global study finds people with haemophilia fight challenges in their professional career but succeed in completing education and getting a job
Taxonomy upgrade extras:
Novo Nordisk A/S - Stock Exchange Announcements
Novo Nordisk A/S - Stock Exchange Announcements
Novo Nordisk A/S - Press Releases
Novo Nordisk A/S - Press Releases